1. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease.
- Author
-
Chaibi FZ, Brier L, Carré P, Landry V, Desmarets L, Tarricone A, Cantrelle FX, Moschidi D, Herledan A, Biela A, Bourgeois F, Ribes C, Ikherbane S, Malessan M, Dubuisson J, Belouzard S, Hanoulle X, Leroux F, Deprez B, and Charton J
- Subjects
- Structure-Activity Relationship, Humans, Cysteine Endopeptidases metabolism, Acylation, Cysteine chemistry, Cysteine pharmacology, Molecular Structure, Dose-Response Relationship, Drug, Protease Inhibitors pharmacology, Protease Inhibitors chemical synthesis, Protease Inhibitors chemistry, Models, Molecular, Drug Design, Crystallography, X-Ray, Coronavirus 3C Proteases antagonists & inhibitors, Coronavirus 3C Proteases metabolism, Antiviral Agents pharmacology, Antiviral Agents chemistry, Antiviral Agents chemical synthesis, SARS-CoV-2 drug effects, SARS-CoV-2 enzymology, Benzimidazoles pharmacology, Benzimidazoles chemistry, Benzimidazoles chemical synthesis
- Abstract
The 3CL protease (3CL
pro , Mpro ) plays a key role in the replication of the SARS-CoV-2 and was validated as therapeutic target by the development and approval of specific antiviral drugs (nirmatrelvir, ensitrelvir), inhibitors of this protease. Moreover, its high conservation within the coronavirus family renders it an attractive therapeutic target for the development of anti-coronavirus compounds with broad spectrum activity to control COVID-19 and future coronavirus diseases. Here we report on the design, synthesis and structure-activity relationships of a new series of small covalent reversible inhibitors of the SARS-CoV-2 3CLpro . As elucidated thanks to the X-Ray structure of some inhibitors with the 3CLpro , the mode of inhibition involves acylation of the thiol of the catalytic cysteine. The synthesis of 60 analogs led to the identification of compound 56 that inhibits the SARS-CoV-2 3CLpro with high potency (IC50 = 70 nM) and displays antiviral activity in cells (EC50 = 3.1 μM). Notably, compound 56 inhibits the 3CLpro of three other human coronaviruses and exhibit a good selectivity against two human cysteine proteases. These results demonstrate the potential of this electrophilic N-acylbenzimidazole series as a basis for further optimization., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Masson SAS.)- Published
- 2024
- Full Text
- View/download PDF